Triple-Hormone Agonist Peptides for Weight Loss
By Charles Kamen, MD, board-certified neurologist
triple-hormone agonists are a next-generation multi-agonist peptide generating significant interest in weight management medicine. Dr. Charles Kamen, MD, board-certified neurologist at LiveNow Longevity in Las Vegas, discusses this emerging therapy and its potential applications. Individual results vary.
What Is triple-hormone agonists
triple-hormone agonists are a single peptide that acts on three different receptors: weight-loss medication, a gut hormone (glucose-dependent insulinotropic polypeptide), and glucagon. This triple agonist mechanism differentiates it from existing dual-agonist peptides like dual-hormone agonists. [1]
The compound was developed by Eli Lilly and has shown impressive weight loss results in clinical trials.
Triple Agonist Mechanism
triple-hormone agonists's three-receptor activation produces combined effects:
- weight-loss medication: Appetite suppression, improved insulin sensitivity, slowed gastric emptying
- a gut hormone: Enhanced glucose metabolism, potential appetite modulation
- Glucagon: Increased energy expenditure, enhanced fat mobilization
Clinical Trial Results
Phase 2 clinical trial results showed remarkable weight loss. Participants receiving the highest triple-hormone agonists dose achieved approximately 24% body weight reduction at 48 weeks — a figure that exceeds most other weight management interventions. [2]
These results are preliminary and Phase 3 trials are ongoing.
Current Status
triple-hormone agonists are not yet FDA-approved. It remains under investigation in clinical trials. Off-label use is not standard practice, and access is limited to clinical trial participants. [3]
Dr. Kamen monitors the research and will consider offering triple-hormone agonists if it receives approval and demonstrates an appropriate safety and efficacy profile.
Key Takeaways
- Triple-hormone agonists are a-action weight-loss medication
- Clinical trials show significant weight loss potential — approximately 24% body weight reduction
- Not yet FDA-approved; still under clinical investigation
- Currently available only to clinical trial participants
- Approval timeline uncertain pending Phase 3 trial completion
- Dr. Kamen will offer triple-hormone agonists if approved and appropriate
Common Questions
When will triple-hormone agonists be available?
Approval timeline depends on Phase 3 trial completion and FDA review. This is not yet determined. Dr. Kamen will offer triple-hormone agonists if it receives approval.
Is triple-hormone agonists better than dual-hormone agonists?
Early data suggests triple-hormone agonists may produce greater weight loss than dual-hormone agonists. However, head-to-head comparison data and long-term safety profiles are not yet available.
What are the side effects of triple-hormone agonists?
Based on trial data, triple-hormone agonists side effects appear similar to other weight-loss medications — primarily gastrointestinal (nausea, diarrhea, constipation). Long-term safety data is limited.
Can I get triple-hormone agonists now?
Currently, triple-hormone agonists are available only through clinical trials. Off-label use is not established. Dr. Kamen can discuss dual-hormone agonists and other available options.
Will triple-hormone agonists replace other weight-loss medications?
Not immediately. Even if approved, triple-hormone agonists will likely have a limited initial supply. Existing medications like dual-hormone agonists will remain important options.
Should I wait for triple-hormone agonists or start therapy now?
For patients who need weight management now, available therapies like dual-hormone agonists and weight-loss medication are effective options. Dr. Kamen helps patients decide based on their individual situation.
triple-hormone agonists represent a promising future option in weight management medicine. Consult with Dr. Kamen about currently available therapies while monitoring emerging treatments.
References
- Coskun T, et al. Nature. 2024;632(8026):901-909.
- Jastreboff AM, et al. N Engl J Med. 2024;390(22):2059-2072.
- FDA. Novel Drug Approvals Pipeline. 2025.
- Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023;389(6):514-526. (Triple-hormone-receptor agonist retatrutide for obesity, phase 2 trial).
Considering Retatrutide in Las Vegas?
Retatrutide remains investigational, and any GLP-class or peptide protocol should be evaluated and monitored by a physician. Learn how a physician-led peptide clinic in Las Vegas approaches individualized, lab-based, supervised care.
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.